Cargando…

Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review

Objective To determine how often health surveys and quality of life evaluations reach different conclusions from those of primary efficacy outcomes and whether discordant results make a difference in the interpretation of trial findings. Design Systematic review. Data sources PubMed, contact with au...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contopoulos-Ioannidis, Despina G, Karvouni, Anastasia, Kouri, Ioanna, Ioannidis, John P A
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628302/ https://www.ncbi.nlm.nih.gov/pubmed/19139138 http://dx.doi.org/10.1136/bmj.a3006

Ejemplares similares

Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment
por: Panagiotou, Orestis A, et al.
Publicado: (2013)

Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis
por: Ioannidis, John P.A., et al.
Publicado: (2023)

International ranking systems for universities and institutions: a critical appraisal
por: Ioannidis, John PA, et al.
Publicado: (2007)

Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey
por: Hemkens, Lars G, et al.
Publicado: (2016)

Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters
por: Ioannidis, John P.A., et al.
Publicado: (2020)

Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities
por: Ioannidis, John P.A., et al.
Publicado: (2021)

Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies
por: Axfors, Cathrine, et al.
Publicado: (2023)

Robustness of reported postacute health outcomes in children with SARS-CoV-2 infection: a systematic review
por: Hirt, Julian, et al.
Publicado: (2023)

Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions
por: Papanikolaou, George N, et al.
Publicado: (2001)

Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials
por: Theodoratou, Evropi, et al.
Publicado: (2014)

Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis
por: Holubar, Marisa, et al.
Publicado: (2017)

1622. Increase in Congenital Toxoplasmosis and Acute Toxoplasmosis Among Pregnant Women in the US during the COVID-19 pandemic
por: Contopoulos-Ioannidis, Despina, et al.
Publicado: (2023)

Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis
por: Contopoulos-Ioannidis, Despina, et al.
Publicado: (2018)

Age-stratified infection fatality rate of COVID-19 in the non-elderly population
por: Pezzullo, Angelo Maria, et al.
Publicado: (2023)

Acute Toxoplasma gondii Infection among Family Members in the United States
por: Contopoulos-Ioannidis, Despina G., et al.
Publicado: (2013)

Toxoplasmosis and Schizophrenia: A Systematic Review and Meta‐Analysis of Prevalence and Associations and Future Directions
por: Contopoulos‐Ioannidis, Despina G., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in Adults and Severe Toxoplasmosis: Similar Clinical Presentations, Potentially Severe Outcomes
por: Ardura, Monica I, et al.
Publicado: (2022)

Clinical Spectrum, Radiological Findings, and Outcomes of Severe Toxoplasmosis in Immunocompetent Hosts: A Systematic Review
por: Layton, John, et al.
Publicado: (2023)

Assessment of transparency indicators across the biomedical literature: How open is open?
por: Serghiou, Stylianos, et al.
Publicado: (2021)

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
por: Strijbis, Eva MM, et al.
Publicado: (2022)

SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements
por: van der Meulen, Merel, et al.
Publicado: (2020)

PRISMA-Children (C) and PRISMA-Protocol for Children (P-C) Extensions: a study protocol for the development of guidelines for the conduct and reporting of systematic reviews and meta-analyses of newborn and child health research
por: Kapadia, Mufiza Z, et al.
Publicado: (2016)

Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination
por: Pastorino, Roberta, et al.
Publicado: (2022)

Do systematic reviews on pediatric topics need special methodological considerations?
por: Farid-Kapadia, Mufiza, et al.
Publicado: (2017)

1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
por: Seddik, Talal B, et al.
Publicado: (2019)

Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study
por: Tzoulaki, Ioanna, et al.
Publicado: (2011)

Validation of the SF-36 in patients with endometriosis
por: Stull, Donald E., et al.
Publicado: (2013)

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies
por: Li, Xue, et al.
Publicado: (2017)

Comparing the SF-12 and SF-36 health status questionnaires in patients with and without obesity
por: Wee, Christina C, et al.
Publicado: (2008)

P value and Bayesian analysis in randomized-controlled trials in child health research published over 10 years, 2007 to 2017: a methodological review protocol
por: Aregbesola, Alex, et al.
Publicado: (2021)

Measurement Comparisons of the Medical Outcomes Study and Veterans SF-36(®) Health Survey
por: Kazis, Lewis E., et al.
Publicado: (2004)

Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension
por: Twiss, James, et al.
Publicado: (2013)

ASSESSMENT BY PROXY OF THE SF-36 AND WHO-DAS 2.0. A SYSTEMATIC REVIEW
por: HERNÁNDEZ, Juan David, et al.
Publicado: (2023)

Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions
por: Cristea, Ioana Alina, et al.
Publicado: (2020)

Psychometric Evaluation of the SF-36(®) Health Survey in Medicare Managed Care
por: Gandek, Barbara, et al.
Publicado: (2004)

Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population
por: Demiral, Yucel, et al.
Publicado: (2006)

Measurement equivalence of the SF-36 in the canadian multicentre osteoporosis study
por: Lix, Lisa M, et al.
Publicado: (2012)

Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies
por: Ioannidis, John P A
Publicado: (2022)

Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
por: Pickard, A Simon, et al.
Publicado: (2005)

Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.1
por: Farivar, Sepideh S, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_tkl5d672ssi9g5fq4bahkq2dkm